Skip to main content

The Money Overview

One costly prescription can hit Medicare’s new 2027 drug ceiling by February

Medicare has already set the 2027 numbers for its Part D out-of-pocket cap, and they’re both moving up: the annual ceiling on covered drug costs rises to $2,400 from $2,100, and the deductible that comes before it rises to $700 from $615. Those figures sound like a distant planning detail for October’s enrollment season, but for someone starting a high-cost specialty drug in January, the entire climb to that $2,400 ceiling can take a single prescription, sometimes closing most of the gap before the first month is even over.

The 2027 Cap, And What Changed From 2026

Once a Part D member’s covered drug spending for the year reaches $2,400 in 2027, the plan pays the rest of that year’s covered prescriptions in full, with no further copay or coinsurance owed. That’s a $300 increase over the $2,100 threshold that applies in 2026, a jump of roughly 14%, and it comes paired with a deductible rising to $700 from $615, also about a 14% increase.

Humana’s separate 2027 Part D changes summary, updated in August, confirms the same $2,400 cap and frames it as part of a broader Inflation Reduction Act redesign becoming permanent in 2027, alongside the expiration of a separate premium-stabilization program that had been cushioning insurers against sharp premium swings. Neither figure is a projection or a rumor; both are the finalized numbers plans must build their 2027 benefit designs around.

The cap functions the same way it did in 2026, just at a higher dollar amount: a member pays the deductible first, then a share of covered drug costs, until total spending toward the cap is reached. UnitedHealthcare’s own 2027 plan-change guidance, published this month, states both figures directly, and every plan nationwide uses the same $2,400 ceiling and $700 deductible ceiling even though the specific drugs a plan covers, and the tier it assigns them, still varies plan by plan.


Free download: What to ask the plan, the prescriber and the pharmacy, when to request an exception, and which records to keep. Download the free prescription coverage checklist.

Why One Prescription Can Do It By February

The arithmetic behind a fast trip to $2,400 is straightforward. A member owes the full $700 deductible before any coinsurance kicks in, leaving $1,700 of the cap still to close during the coinsurance stage that follows. Under Part D’s standard cost-sharing design, that stage requires roughly $6,800 in additional drug costs to generate $1,700 in member cost-sharing, meaning a member whose covered drugs cost about $7,500 or more in total reaches the $2,400 ceiling on their own spending alone.

Specialty drugs routinely cost far more than that in a single month. CMS’s own data on drugs selected for Medicare’s second round of price negotiations shows just how concentrated those costs are: Xtandi, a prostate-cancer drug, generated about $3.16 billion in Part D spending across only 35,000 enrollees in a year, or roughly $90,000 per enrollee. Pomalyst, used for multiple myeloma, ran closer to $148,000 per enrollee, and Ibrance, a breast-cancer drug, averaged around $124,000 per enrollee over the same period, according to CMS’s fact sheet on the negotiated drug list.

Those are program-wide annual averages, not any single patient’s own out-of-pocket bill, but they show that a month’s supply of many specialty cancer or immune-disorder drugs runs well past the $7,500 mark that closes out the 2027 cap. CMS’s own fact sheet on the negotiated drug list shows those aren’t outlier cases either: several of the 15 drugs chosen for Medicare’s second negotiation round carry six-figure annual costs concentrated among a few thousand enrollees each. A member starting one of these drugs in January, or refilling it in February, can reasonably cross the entire $2,400 ceiling within the first one or two fills of the year, long before spring enrollment deadlines or tax season even arrive.

The Premium Keeps Going Even After The Cap Is Reached

Reaching the $2,400 cap zeroes out a member’s cost-sharing on covered drugs for the rest of the year, but it does nothing to the monthly Part D premium, which is billed on its own separate schedule regardless of what stage a member has reached. A member who hits the cap in February is still paying the same premium in March as someone who never fills a single covered prescription all year.

The cap also doesn’t carry forward. It resets every January 1, so a member who spent months at $0 cost-sharing in late 2026 starts over at the $700 deductible again under the higher 2027 numbers, with no credit for how quickly they reached the old cap the year before. For someone on an ongoing specialty drug, that reset can mean a sharp cost spike in January even after a stretch of months paying nothing.

The reliable way to know exactly where those 2027 figures stand is the source both major insurers point back to: the federal government’s own Part D benefit parameters, which UnitedHealthcare and Humana both cite directly rather than estimate, putting the 2027 out-of-pocket cap at $2,400 and the deductible at $700, up from $2,100 and $615 this year.


Watching A Specialty Drug’s Climb Toward The 2027 Cap

The annual drug-cost ceiling is a hard number, but nothing on a monthly plan statement shows a member how close one expensive fill has already pushed them toward it, and any appeal for a lower-tier alternative has to happen before that fill, not after the bill arrives.

The Medicare Cost & Coverage Protection Kit is a 10-page kit built around the new Part D out-of-pocket cap, the prior-authorization appeal steps, and a medication and cost tracker for logging exactly what a specialty prescription costs toward it.

Track a specialty drug’s cost against the cap with The Medicare Cost & Coverage Protection Kit.

This article was researched and drafted with the assistance of AI and reviewed by The Money Overview editorial team.


More in Social Security & Medicare